46.80
price up icon0.00%   0.00
after-market 시간 외 거래: 46.75 -0.05 -0.11%
loading

Springworks Therapeutics Inc 주식(SWTX)의 최신 뉴스

pulisher
03:30 AM

RFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

03:30 AM
pulisher
Jun 05, 2025

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Squarepoint Ops LLC - MarketBeat

Jun 05, 2025
pulisher
Jun 04, 2025

(SWTX) Proactive Strategies - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 04, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 19,315 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

Jun 04, 2025
pulisher
Jun 03, 2025

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc.SWTX - Business Wire

Jun 03, 2025
pulisher
Jun 02, 2025

Nuveen Asset Management LLC Has $6.64 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

Jun 02, 2025
pulisher
Jun 02, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 01, 2025

$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - Benzinga

Jun 01, 2025
pulisher
May 31, 2025

BNP Paribas Financial Markets Acquires Shares of 9,719 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 31, 2025
pulisher
May 30, 2025

Promising Growth Stocks To Research – May 28th - Defense World

May 30, 2025
pulisher
May 29, 2025

ProShare Advisors LLC Acquires 5,503 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 29, 2025
pulisher
May 28, 2025

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Deutsche Bank AG Purchases 19,540 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Merck, SpringWorks receive German antitrust approval for their deal - MLex

May 28, 2025
pulisher
May 28, 2025

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Palisades Investment Partners LLC Purchases 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 28, 2025
pulisher
May 27, 2025

Bank of America Corp DE Reduces Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 27, 2025
pulisher
May 27, 2025

SpringWorks Therapeutics (SWTX) Surged on Acquisition News - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World

May 27, 2025
pulisher
May 26, 2025

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease - Nasdaq

May 26, 2025
pulisher
May 26, 2025

SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com

May 26, 2025
pulisher
May 26, 2025

142,300 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Zimmer Partners LP - MarketBeat

May 26, 2025
pulisher
May 25, 2025

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges - Investing.com

May 25, 2025
pulisher
May 25, 2025

Growth Stocks To Consider – May 23rd - Defense World

May 25, 2025
pulisher
May 25, 2025

Growth Stocks To ConsiderMay 23rd - MarketBeat

May 25, 2025
pulisher
May 25, 2025

(SWTX) Investment Analysis - news.stocktradersdaily.com

May 25, 2025
pulisher
May 25, 2025

SpringWorks Therapeutics receives positive CHMP opinion for Mirdametinib for the treatment of adult and paediatric patients with NF1-PN | Health & Wellbeing | Lifestyle - The Phoenix Newspaper UK

May 25, 2025
pulisher
May 25, 2025

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase – Time to Buy? - Defense World

May 25, 2025
pulisher
May 25, 2025

Woodline Partners LP Raises Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 25, 2025
pulisher
May 24, 2025

Rafferty Asset Management LLC Has $4.44 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 24, 2025
pulisher
May 24, 2025

Velan Capital Investment Management LP Acquires Shares of 185,520 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 24, 2025
pulisher
May 24, 2025

Tema Etfs LLC Takes $1.11 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

May 24, 2025
pulisher
May 23, 2025

SpringWorks’ drug nears EU approval for neurofibromatosis treatment By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics (SWTX) Gains EMA Panel Support for Mird - GuruFocus

May 23, 2025
pulisher
May 23, 2025

SpringWorks gets EU endorsement for genetic disorder treatment - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

SpringWorks’ drug nears EU approval for neurofibromatosis treatment - Investing.com Australia

May 23, 2025
pulisher
May 23, 2025

Springworks Therapeutics Says Mirdametinib Recommended by EU Panel for Treating Plexiform Neurofibromas - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

SpringWorks: CHMP Adopts Positive Opinion For Mirdametinib - Nasdaq

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mird - GuruFocus

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics (SWTX) Receives Positive Opinion from E - GuruFocus

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics (SWTX) Receives Positive Opinion from EMA for Mirdametinib | SWTX Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics Reports Positive CHMP Opinion for Mirdametinib as Potential First Therapy for NF1-PN in EU - Nasdaq

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics Inc. (SWTX) Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - StreetInsider

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics Receives Positive CHMP Opinion for - GlobeNewswire

May 23, 2025
pulisher
May 23, 2025

Breakthrough NF1-PN Treatment Scores 52% Response Rate in Children as EU Approval Looms - Stock Titan

May 23, 2025
pulisher
May 23, 2025

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

May 23, 2025
pulisher
May 23, 2025

Deutsche Bank AG Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World

May 23, 2025
pulisher
May 22, 2025

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Ensign Peak Advisors Inc - MarketBeat

May 22, 2025
$1.15
price up icon 0.00%
$585.93
price up icon 0.92%
$300.83
price down icon 2.33%
$38.11
price up icon 4.30%
$4.73
price down icon 1.69%
$493.22
price up icon 2.10%
자본화:     |  볼륨(24시간):